People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immune-Onc Therapeutics, Inc. | — | Biotechnology | Series A | $7.0M | $253.2M | 2016 |
| Nvigen, Inc. | — | Biotechnology | Seed | $2.1M | $49.6M | — |
Guo-Liang Yu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Guo-Liang Yu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Guoliang Yu | 1 | 4 |
| Xiaoling Charlene Liao | 1 | 1 |
| Liqun Luo | 1 | 1 |
| Xiangdong Jin | 1 | 1 |
| Aihua Fu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.